<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20120330//EN" "JATS-journalpublishing1.dtd">
<article xml:lang="KO" article-type="research-article">

<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Tuberc Respir Dis</journal-id>
<journal-id journal-id-type="publisher-id">TRD</journal-id>
<journal-title-group>
<journal-title>Tuberculosis and Respiratory Diseases</journal-title>
</journal-title-group>
<issn pub-type="ppub">0378-0066</issn>
<publisher>
<publisher-name>The Korean Academy of Tuberculosis and Respiratory Diseases</publisher-name>
</publisher>
</journal-meta>

<article-meta>
<article-id pub-id-type="doi">10.4046/trd.2004.56.5.514</article-id>
<article-categories>
<subj-group>
<subject>Original Article</subject>
</subj-group>
</article-categories>

<title-group>
<article-title>Growth Inhibition and Apoptosis Induction of Sulindac on Human Lung Cancer Cells</article-title>
</title-group>

<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Kim</surname>
<given-names>Hak Ryul</given-names>
</name>
<degrees>M.D.</degrees>
<xref ref-type="aff" rid="A1"></xref>
</contrib>

<contrib contrib-type="author" corresp="yes">
<name>
<surname>Yang</surname>
<given-names>Sei Hoon</given-names>
</name>
<degrees>M.D.</degrees>
<xref ref-type="aff" rid="A1"></xref>
</contrib>

<contrib contrib-type="author">
<name>
<surname>Jeong</surname>
<given-names>Eun Taik</given-names>
</name>
<degrees>M.D.</degrees>
<xref ref-type="aff" rid="A1"></xref>
</contrib>

</contrib-group>

<aff id="A1">Department of Internal Medicne, Wonkwang University College of Medicne, Iksan, Korea.</aff>

<author-notes>
<corresp>
Address for correspondence: Sei Hoon Yang, M.D. Department of Internal Medicine, Wonkwang University College of Medicine 344-2, Shinyong-dong, Iksan, Jeonbuk, 570-711, Korea. Phone: 0653) 850-1078, Fax: 0653) 855-2025, <email>yshpul@wonkwang.ac.kr</email>
</corresp>
</author-notes>

<pub-date pub-type="ppub">
<month>05</month>
<year>2004</year>
</pub-date>
<pub-date pub-type="epub">
<day>31</day>
<month>05</month>
<year>2004</year>
</pub-date>
<volume>56</volume>
<issue>5</issue>
<fpage>514</fpage>
<lpage>522</lpage>

<permissions>
<copyright-statement>Copyright&#x00A9;2004. The Korean Academy of Tuberculosis and Respiratory Diseases. All rights reserved.</copyright-statement>
<copyright-year>2004</copyright-year>
</permissions>

<abstract>
<sec>
<title>Background</title>
<p>Non-steroidal anti-inflammatory drugs (NSAID) are useful in chemoprevention of colorectal cancers. Continuous NSAID administation causes 40&#x0025; to 50&#x0025; reduction in relative risk for colorectal cancer. Sulindac possesses an antiproliferative effect and induces apoptosis and tumor regression on colon cancer and other types of cancers. We intended to analyze the effects of sulindac in three non-small cell lung cancer cell lines.</p>
</sec>
<sec>
<title>Materials and Methods</title>
<p>The human lung cancer cell lines, A549, NCI-H157 and NCI-H460 were used for this study. Viability was tested by MTT assay, and cell death rate was measured by lactate dehydrogenase(LDH) release. Apoptosis was estimated by flow cytometric analysis and nuclear staining.</p>
</sec>
<sec>
<title>Results</title>
<p>Sulindac was able to decrease the viability of non-small cell lung cancer cells in a dose- and time- dependent manner. In a parallel effect of sulindac on cell death rate, LDH release was increased in sulindac-treated lung cancer cells. Sulindac significantly increased apoptosis characterized by an increase of sub-G<sub>0</sub>/G<sub>1</sub> fraction and morphological change of nuclei. The rate of apoptotic cells after sulindac treatment in lung cancer cells increased in a time- and dose- dependent manner in flow cytometric analysis. Apoptotic cells were defined as nuclear shrinkage, chromatin condensation and nuclear fragmentation of cells.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>Sulindac decreases viability and induces the apoptosis of lung cancer cells. Further studies will be needed to elucidate the potential mechanism of sulindac-induced apoptosis in lung cancer cells.</p>
</sec>
</abstract>

<kwd-group>
<kwd>Lung cancer</kwd>
<kwd>Sulindac</kwd>
<kwd>Apoptosis</kwd>
</kwd-group>

</article-meta>
</front>
</article>


